Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jiangsu Kanion Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:600557'
s EV-to-FCF Range Over the Past 10 Years
Min: -465.87 Med: 17.09 Max: 361.68
Current: -427.52
During the past 13 years, the highest EV-to-FCF of Jiangsu Kanion Pharmaceutical Co was 361.68. The lowest was -465.87. And the median was 17.09.
SHSE:600557's EV-to-FCF is ranked worse than 100% of 563
companies
in the Drug Manufacturers industry
Industry Median: 21.03
vs SHSE:600557: -427.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Kanion Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Kanion Pharmaceutical Co's share price for today is ¥13.63.
Jiangsu Kanion Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jiangsu Kanion Pharmaceutical Co EV-to-FCF Related Terms
Jiangsu Kanion Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Kanion Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Kanion Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Kanion Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jiangsu Kanion Pharmaceutical Co's EV-to-FCF falls into.
Jiangsu Kanion Pharmaceutical Co's current Enterprise Value is ¥5,678 Mil.
Jiangsu Kanion Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) has a EV-to-FCF of -426.25 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jiangsu Kanion Pharmaceutical Co and its competitors. According to the industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #999999 out of 563 companies in the Drug Manufacturers industry.
Is Jiangsu Kanion Pharmaceutical Co's EV-to-FCF too high?
Jiangsu Kanion Pharmaceutical Co's current EV-to-FCF is -426.25. Based on the distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #999999 out of 563 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Kanion Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Kanion Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #999999 out of 563 companies for EV-to-FCF. This places Jiangsu Kanion Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 21.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.03, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jiangsu Kanion Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Kanion Pharmaceutical Co's current EV-to-FCF is -426.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Kanion Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co (SHSE:600557) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.70, compared to a current price of ¥13.63 — trading 0.5% below its estimated fair value. The current EV-to-FCF is -426.25. Jiangsu Kanion Pharmaceutical Co's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jiangsu Kanion Pharmaceutical Co (SHSE:600557), the current EV-to-FCF is -426.25 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Kanion Pharmaceutical Co (SHSE:600557) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥13.63 is trading 0.5% below its estimated GF Value™ of ¥13.70.
GuruFocus considers Jiangsu Kanion Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600557:
EV-to-FCF: -426.25
GF Value™: ¥13.70 vs. price of ¥13.63 (0.5% below fair value)
No single metric tells the full story. See the SHSE:600557 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Kanion Pharmaceutical Co Business Description
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
82GF Score
Get the complete analysis for SHSE:600557
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600557 has been successfully added to your 
